Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Lipella Pharmaceuticals LIPO shares increased by 158.9% to $6.68 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 million. MBX Biosciences MBX stock moved ...

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD), a clinical-stage biotechnology firm with a market capitalization of $11.5 million, has announced the acquisition of Sepranolone, a Phase ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...

Relmada Therapeutics, Inc. has recently received a notice from the Nasdaq Stock Market indicating that the company’s security did not maintain a minimum bid price of $1 per share for the 30 ...

Inc., a pharmaceutical company currently trading at $0.39 and showing a significant 89% decline over the past year according to InvestingPro data, has been alerted by the Nasdaq Stock Market of ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.